JY231 therapy for B-cell leukemia that has returned
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new therapy called JY231 for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. It aims to see if this therapy can help control the leukemia and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment.
- Your cancer cells must have a specific marker called CD19 (usually confirmed by a biopsy).
- You must have some remaining leukemia cells in your bone marrow or blood, as shown by tests.
- Your liver and kidney function must be within acceptable limits, and your platelet count at least 20,000.
- You should be generally healthy (able to do daily activities) and not have active infections or other serious health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called JY231 for people whose B-cell lymphoma or leukemia has come back or not responded to standard treatments. The therapy targets a protein on cancer cells called CD19 and may help your immune system fight the cancer.
This trial tests a new cell therapy (JY231) for people with B-cell lymphoma or B-cell acute lymphoblastic leukemia (B-ALL) that has come back or didn't respond to previous treatments. The therapy targets a marker on cancer cells called CD19 and aims to help your body fight the cancer.
This trial tests a new injectable treatment (called JY231) for people whose B-cell lymphoma has come back or did not respond to standard treatments. The treatment targets a specific marker on cancer cells (CD19) and may help when other options have not worked.
This trial tests a new drug called JMT601 for people with a type of B-cell lymphoma that came back or didn't respond to at least two previous treatments. The drug targets a protein on the cancer cells to help your immune system fight the disease.
This trial tests a new cell therapy (JY231) for people whose B-cell lymphoma or leukemia (B-ALL) has returned or not responded to earlier treatments. The therapy uses your own T cells, modified to target the CD19 marker on cancer cells.
This trial tests a new injection called JY231 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. The therapy targets a protein called CD19 on cancer cells, helping your immune system attack them.
Hear when a new B-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.